Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced HER2+Breast Cancer × Alpelisib × Breast × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 45 Neoplasm Metastasis 4 Hereditary Sensory and Autonomic Neuropathies 4 Triple Negative Breast Neoplasms 3 Ovarian Neoplasms 3 Neoplasms 3 Hyperglycemia 3 Multiple Endocrine Neoplasia Type 1 2 Advanced Breast Cancer 2 Sarcoma 1 Recurrence 1 Prostatic Neoplasms 1 Pre-menopausal Breast Cancer 1 Pancreatic Neoplasms 1 Kidney Neoplasms 1 Hormone Receptor Positive Breast Carcinoma 1 Head and Neck Neoplasms 1 HER2-positive Metastatic Breast Cancer 1 Genetic Diseases, Inborn 1 Gastrointestinal Neoplasms 1 Exanthema 1 Endometrial Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Ductal, Breast 1 Anatomic Stage III Breast Cancer AJCC v8 1 Advanced or Metastatic ER+ Breast Cancer 1 Advanced Solid Tumors With an Alteration of the PIK3CA Gene 1 Advanced HER2+Breast Cancer 1 Acrocephalosyndactylia 1

Interventions

pertuzumab 1 Trastuzumab 1 Alpelisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04208178 2026-02-02

EPIK-B2

Novartis

Phase 3 Active not recruiting

Advanced HER2+Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡